Baris Malbora

Baris Malbora

Auto-generated profile, based on publicly available information

Baris Malbora

Department of Paediatric Haematology and Oncology, Gaziosmanpaşa Hospital, Istanbul Yeni Yüzyıl University, 34010 Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2015 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MAMeltem Akcaboy
Meltem Akcaboy
BMBaris Malbora
Baris Malbora
PZPelin Zorlu
Pelin Zorlu
EAEsma Altınel
Esma Altınel
MOMelahat Melek Oguz
Melahat Melek Oguz
SSSaliha Senel
Saliha Senel

1 May 2009 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
BMBaris Malbora
Baris Malbora
EOEmel Ozyurek
Emel Ozyurek
AKAysu Inan Kocum
Aysu Inan Kocum
NONamik Ozbek
Namik Ozbek
A 10-year-old girl who presented to our hospital was diagnosed as having B-precursor cell acute lymphoblastic leukemia. St Jude's Total XIII protocol was started. In the second block of the consolidation phase, 10 hours after triple intrathecal treatment, we realized that instead of 12 mg, 120 mg of methotrexate had accidentally been given. Although the patient had no symptoms 10 hours after intrathecal treatment, to prevent the possible neurotoxic effects of methotrexate, a cerebrospinal fluid exchange was performed. Simultaneously, systemic dexamethasone and calcium folinic acid were given. At the time of this writing (2 y), the patient has had no symptoms and has continued on the chemotherapy protocol as planned. Administration of high-dose intrathecal methotrexate may not lead to symptoms, as was the case in our patient. This may be related to individual variations in cerebrospinal fluid dynamics and drug metabolism.

1 March 2014 in Turkish Journal of Hematology
Verified
Journal Article
Open access
FHFerda Özbay Hoşnut
Ferda Özbay Hoşnut
FÖFigen Özçay
Figen Özçay
BMBarış Malbora
Barış Malbora
ŞHŞamil Hızlı
Şamil Hızlı
NÖNamık Özbek
Namık Özbek

17 March 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
AYAyça Koca Yozgat
Ayça Koca Yozgat
GLGöksel Leblebisatan
Göksel Leblebisatan
SASinan Akbayram
Sinan Akbayram
SÖSimge Çınar Özel
Simge Çınar Özel
ZKZeynep Karakaş
Zeynep Karakaş
NÖNamık Yaşar Özbek
Namık Yaşar Özbek
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.

29 September 2022 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
GGGülçin Özalp Gerçeker
Gülçin Özalp Gerçeker
BYBüşra Güliz Yildirim
Büşra Güliz Yildirim
ASAyşe Arıcıoğlu Sülün
Ayşe Arıcıoğlu Sülün
MBMurat Bektas
Murat Bektas
HÖHamiyet Hekimci Özdemir
Hamiyet Hekimci Özdemir
BMBarış Malbora
Barış Malbora

25 June 2010 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PDF file
BMBaris Malbora
Baris Malbora
EOEmel Ozyurek
Emel Ozyurek
SYSelman Vefa Yildirim
Selman Vefa Yildirim
ZAZekai Avci
Zekai Avci
NONamik Ozbek
Namik Ozbek
Cardiac complications of the pediatric patients with acute leukemia are common. Most of the cardiac complications may be due to chemotherapeutics such as antracyclins, besides anemia, infections, or direct leukemic infiltrations of the heart. It is reported that leukemic infiltration is frequent in the postmortem examination of the myocardium and pericardium. However, at the antemortem examination, pericardial involvement is rare and there is no myocardial involvement reported at the time of diagnosis in patients with acute leukemia in the English literature. Here, the authors report an adolescent with acute lymphoblastic leukemia who had myocardial infiltration at the time of diagnosis.